Alnylam Pharmaceuticals Inc to Discuss FDA Approval of AMVUTTRA (Vutrisiran) Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Eliana Rachel Merle - UBS Investment Bank, Research Division - Analyst : Congrats on the approval. Maybe just from your, I guess, commercial conversations with physicians and patients, how are you thinking about how much sort of subcu and added convenience could accelerate uptake in growth, particularly in sort of the mixed phenotype with cardiomyopathy segment? Anything you're hearing in terms of feedback as well as how you're thinking about focus in the commercialization strategies just? And how you're targeting neurologists versus cardiologists?

Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst : And my congrats as well. How would you characterize what the access for ONPATTRO has been, your experience there so far? And would you expect AMVUTTRA to be similar or maybe even better given the profile of the drug that you highlighted? And will there be good access for both the PN and the mixed patients as you're highlighting them? And then I guess with all the patient assistance, what do you expect the gross to net to be in the early phases of the launch?

Question: Myles Robert Minter - William Blair & Company L.L.C., Research Division - Analyst : Just a follow-up to that question. Like are we expecting for the value-based agreements that efficacy would have to look something like what we're seeing in the prescribing label? Or is it more just like a clinician global improvement scale or something like that is communicated to the payer. Just wondering if there's any sort of key specific aspects of AMVUTTRA's risk benefit that need to be communicated to that payer to achieve actual reimbursement here?